Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 24;6:26611. doi: 10.1038/srep26611

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Genetically engineered miR-34a prodrug was processed to mature miR-34a in human osteosarcoma 143B cells (A), which consequently reduced the protein expression of miR-34a target genes including SIRT1, BCL2, CDK6 and c-MET (B). Cells were harvested at 72 h after treatment with tRNA/mir-34a or control tRNA/MSA, or vehicle. Mature miR-34a levels were quantitated by selective stem-loop reverse transcription RT-qPCR assay, and normalized to U6 levels. Protein was detected by Western blot analyses, and GAPDH was used as a loading control. Values are mean ± SD of triplicate treatments. ***P < 0.001 (one-way ANOVA), as compared with tRNA/MSA or vehicle control treatment.

HHS Vulnerability Disclosure